Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Tom Frohlich
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 55
- Beta
- 1.45
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 15.18
Financials
Net Income
$-55.77MEBITDA
$-58.91MFree Cash Flow
$-43.66MEPS (diluted)
$-0.76Shares Outstanding (diluted)
61.05M+7630.6%Operating Expenses
$58.91MCash & Debt
$461.20MDividend per Share
$2.40Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-127.41M | $-4.06 |
| 2024 | $0.00 | $-69.63M | $-85.26 |
| 2023 | $0.00 | $-75.52M | $-100.38 |
| 2022 | $0.00 | $-51.51M | $-73.67 |
| 2021 | $0.00 | $-22.96M | $-32.96 |
| 2020 | $0.00 | $-9.61M | $-14.00 |
Valuation
JBIOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+50.00%Social Signal Score
Mentions (3)
- Newsseekingalpha.com·5d ago·Positive
Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis Transcript Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis Transcript
View source ↗ - Newsglobenewswire.com·35d ago·Positive
Jade Biosciences to Participate in Upcoming Conferences SAN FRANCISCO and VANCOUVER, British Columbia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences: Wells Fargo 21st Annual Healthcare Conference Fireside Chat: Tuesday, September 8 at 3:45 p.m.
View source ↗ - Newsseekingalpha.com·47d ago·Negative
Jade Biosciences: Duration Is The Real Product Jade Biosciences (JBIO) targets IgAN with JADE101, aiming for quarterly dosing that could significantly improve patient adherence versus competitors' more frequent regimens. Phase 1 data show JADE101 achieves ~70% IgA reduction with a favorable safety profile; Phase 2 JUNIPER trial interim data expected in 2027 will be pivotal. JBIO's pipeline includes JADE201 (anti-BAFF-R antibody) and JADE301 (IFN-beta inhibitor), both engineered for extended-inte…
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.73 per share
Typical surprise -9.6% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.76 vs $-0.64miss
- Thu, May 7$-0.57 vs $-0.52miss
- Fri, Mar 6$-0.45 vs $-0.45beat
- Fri, Nov 14$-0.48 vs $-0.57beat
- Thu, Aug 14$-0.86 vs $-0.43miss
- Fri, Apr 25$-12.10 vs $-6.03miss
Estimates and results for JBIO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by JBIO officers and directors.
- Bought
- $44k
- Sold
- —
1 trade
0 trades
- Frohlich Tombought
48 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in JBIO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.